SANGAMO THERAPEUTICS, INC 8-K

What Happened
Sangamo Therapeutics, Inc. (SGMO) filed an 8-K on February 3, 2026 announcing two material items: a preliminary estimate of its cash and cash equivalents of approximately $20.9 million as of December 31, 2025 (Item 2.02), and the departure of its principal financial officer, Prathyusha Duraibabu, effective February 2, 2026, followed by the appointment of Nikunj Jain as Interim Chief Financial Officer effective February 3, 2026 (Item 5.02).

Key Details

• Cash and cash equivalents: approximately $20.9 million as of December 31, 2025 (preliminary estimate).
• CFO change: Prathyusha Duraibabu’s employment terminated February 2, 2026.
• Interim CFO: Nikunj Jain (previously Vice President, Finance and Corporate Controller and principal accounting officer) appointed effective February 3, 2026.
• Compensation/relationships: No additional compensation for Mr. Jain in connection with the interim role; no family relationships or related-party transactions reported; his bio and compensation details are incorporated by reference from the company’s Sep 30, 2025 Form 8-K.

Why It Matters
The company’s disclosed cash balance is a key indicator of near-term liquidity and the resources available to fund operations, development programs, and other obligations. The change in the company’s principal financial officer is material because the CFO handles financial reporting and investor communications; Sangamo appointed an internal, existing finance executive as interim CFO with no additional compensation disclosed, which may limit disruption. Investors should watch subsequent filings (quarterly results, cash-flow updates, and any financing announcements) for updated liquidity, operational progress, and a permanent CFO appointment.